Physician profile
Joseph Seibert
NPI 1518904879
$5,799.44
in general payments reported to CMS, 2019-2025
35 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $1,413 · 2021: $1,268 · 2022: $1,143 · 2023: $938 · 2024: $491 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,642.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $775.24 | 2019-2024 | |
| Novo Nordisk INC | $710.42 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $667.11 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $576.24 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $550.68 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amarin Pharma, INC. | $364.25 | 2019-2021 | |
| Glaxosmithkline, LLC. | $317.70 | 2020-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $304.91 | 2019-2023 | Xarelto |
| Abbott Laboratories | $217.92 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $175.44 | 2019-2021 | |
| Exact Sciences Corporation | $143.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $135.87 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $131.98 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $81.57 | 2021-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $78.40 | 2020-2023 | Trintellix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $65.24 | 2025 | Sapien 3 Ultra Resilia |
| Genentech USA, INC. | $47.62 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $40.35 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.18 | 2020-2022 | |
| Astellas Pharma US INC | $39.35 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.20 | 2021-2022 | |
| Eisai INC. | $35.66 | 2021 | |
| Lundbeck LLC | $32.89 | 2023-2024 | Rexulti |
| Biogen, INC. | $29.56 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.56 | 2019-2024 | Camzyos |
| Allergan, INC. | $24.91 | 2020 | |
| Inspire Medical Systems, INC. | $22.97 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $18.35 | 2023 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.51 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $17.13 | 2020 | |
| Gilead Sciences, INC. | $16.15 | 2021 | |
| Sanofi Pasteur INC. | $15.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.54 | 2022 | |
| Horizon Therapeutics Plc | $12.79 | 2020 | |
| Dynavax Technologies Corporation | $10.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Seibert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.